Skip to content
1st March 2026

Retreatment with BarzolvolimabLeads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria

27th February 2026

Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria

27th February 2026

Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria

6th November 2025

Sustained Efficacy and Safety of Barzolvolimab in Chronic Inducible Urticaria

30th October 2025

Dual targeting of Mast Cells and TSLP with the bispecific antibody CDX-622

17th September 2025

Barzolvolimab Treatment Improves Urticaria Activity in Patients with Chronic Spontaneous Urticaria Regardless of Baseline IgE Levels

14th June 2025

Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from 52 Weeks of Treatment

13th June 2025

Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

1st May 2025

Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Trial of Barzolvolimab

1st March 2025

Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria: Phase 2 12 Week Results

Top